Shared Care

Shared Care Protocols outline prescribing and monitoring responsibilities for the specialist and the GP.

Shared Care Protocols (SCPs) are used to allow prescribing to be taken on by a patient's GP once the patient is stable.

If you are a clinician and want to develop a shared care protocol please click here to contact us.

Below is a list of approved Shared Care Protocols:

• ADHD adult - dexamfetamine information sheet (547 kb) Review date: March 2022
• ADHD adult - lisdexamfetamine information sheet (549 kb) Review date: March 2022
• ADHD adult - methylphenidate information sheet (572 kb) Review date: March 2022
• ADHD adult - shared care protocol (618 kb) Review date: March 2022
• ADHD adult- atomoxetine information sheet (554 kb) Review date: March 2022
• ADHD children and young people - atomoxetine information sheet (652 kb) Review date: December 2022
• ADHD children and young people - dexamfetamine information sheet (551 kb) Review date: December 2022
• ADHD children and young people - lisdexamfetamine information sheet (557 kb) Review date: December 2022
• ADHD children and young people - methylphenidate information sheet (608 kb) Review date: December 2022
• ADHD children and young people - shared care protocol (636 kb) Review date: December 2022
• Amiodarone - information sheet (736 kb) Review date: August 2024
• Amiodarone - overarching SCP (642 kb) Review date: August 2024
• Auto-immune Hepatitis- azathioprine information sheet (711 kb) Review date: Sep 2023
• Auto-immune Hepatitis- overarching SCP (663 kb) Review date: Sep 2023
• Dermatological conditions- azathioprine information sheet (789 kb) Review date: November 2023
• Dermatological conditions- hydroxychloroquine information sheet (104 kb) Review date: May 2023
• Dermatological conditions- methotrexate information sheet (766 kb) Review date: November 2023
• Dermatological conditions- overarching scp (242 kb) Review date: November 2023
• Dronedarone- information sheet (167 kb) Review date: Jan 2022
• Dronedarone- overarching SCP (162 kb) Review date: Jan 2022
• Growth hormone - information sheet (310 kb) Review date: Jan 2022
• Growth hormone - overarching SCP (190 kb) Review date: Jan 2022
• Inflammatory bowel disease - Azathioprine for children >12 years (264 kb) Review date: June 2022
• Inflammatory bowel disease - azathioprine information sheet (874 kb) Review date: Nov 2023
• Inflammatory bowel disease - mercaptopurine information sheet (879 kb) Review date: Nov 2023
• Inflammatory bowel disease - overarching SCP (246 kb) Review date: Nov 2023
• Inflammatory boweldisease - Methotrexate information sheet (777 kb) Review date: Nov 2023
• Neuroinflammatory conditions - azathioprine information sheet (638 kb) Review date: November 2023
• Neuroinflammatory conditions - azathioprine overarching SCP (701 kb) Review date: November 2023
• Neuroinflammatory conditions - azathioprine PIL (128 kb) Review date: November 2023
• Parkinson's disease - apomorphine information sheet (225 kb) Review date: Jan 2023
• Parkinson's disease - overarching SCP (407 kb) Review date: Jan 2023
• Phosphate binders - information sheet (174 kb) Review date: Oct 2022
• Phosphate Binders - overarching SCP (213 kb) Review date: October 2022
• Rheumatological conditions - azathioprine information sheet (351 kb) Review date: July 2023
• Rheumatological conditions - ciclosporin information sheet (427 kb) Review date: July 2023
• Rheumatological conditions - DMARDs Summary of Monitoring (528 kb) Review date: July 2023
• Rheumatological conditions - hydroxychloroquine information sheet (105 kb) Review date: July 2023
• Rheumatological conditions - injectable gold information sheet (352 kb) Review date: July 2023
• Rheumatological conditions - leflunomide information sheet (359 kb) Review date: July 2023
• Rheumatological conditions - methotrexate information sheet (365 kb) Review date: July 2023
• Rheumatological conditions - overarching SCP (223 kb) Review date: July 2023
• Rheumatological conditions - penicillamine information sheet (340 kb) Review date: July 2023
• Rheumatological conditions - sulphasalazine information sheet (356 kb) Review date: July 2023
• Riluzole for Motor Neurone Disease- Information Sheet (545 kb) Review date: April 2024
• Riluzole for Motor Neurone Disease- Overarching SCP (631 kb) Review date: April 2024
• Testosterone (Sustanon) IM administration guide (60 kb)
• Testosterone for Hypogonadism and Constitutional Delay in Growth and Puberty in children and adolescents; Overarching Shared Care Protocol (147 kb) Review date: Jan 2023
• Testosterone in male children and adolescents; Information Sheet (111 kb) Review date: Jan 2023